Observational cohort study of rilpivirine (RPV) utilization in Europe.
Cohort Study
Edurant™
Efavirenz
Europe
Eviplera™
Real-world effectiveness
Journal
AIDS research and therapy
ISSN: 1742-6405
Titre abrégé: AIDS Res Ther
Pays: England
ID NLM: 101237921
Informations de publication
Date de publication:
06 08 2022
06 08 2022
Historique:
received:
10
01
2022
accepted:
16
06
2022
entrez:
6
8
2022
pubmed:
7
8
2022
medline:
10
8
2022
Statut:
epublish
Résumé
Data on safety and effectiveness of RPV from the real-world setting as well as comparisons with other NNRTIs such as efavirenz (EFV) remain scarce. Participants of EuroSIDA were included if they had started a RPV- or an EFV-containing regimen over November 2011-December 2017. Statistical testing was conducted using non-parametric Mann-Whitney U test and Chi-square test. A logistic regression model was used to compare participants' characteristics by treatment group. Kaplan-Meier analysis was used to estimate the cumulative risk of virological failure (VF, two consecutive values > 50 copies/mL). 1,355 PLWH who started a RPV-based regimen (11% ART-naïve), as well as 333 initiating an EFV-containing regimen were included. Participants who started RPV differed from those starting EFV for demographics (age, geographical region) and immune-virological profiles (CD4 count, HIV RNA). The cumulative risk of VF for the RPV-based group was 4.5% (95% CI 3.3-5.7%) by 2 years from starting treatment (71 total VF events). Five out of 15 (33%) with resistance data available in the RPV group showed resistance-associated mutations vs. 3/13 (23%) among those in the EFV group. Discontinuations due to intolerance/toxicity were reported for 73 (15%) of RPV- vs. 45 (30%) of EFV-treated participants (p = 0.0001). The main difference was for toxicity of central nervous system (CNS, 3% vs. 22%, p < 0.001). Our estimates of VF > 50 copies/mL and resistance in participants treated with RPV were similar to those reported by other studies. RPV safety profile was favourable with less frequent discontinuation due to toxicity than EFV (especially for CNS).
Identifiants
pubmed: 35933352
doi: 10.1186/s12981-022-00457-0
pii: 10.1186/s12981-022-00457-0
pmc: PMC9357334
doi:
Substances chimiques
Anti-HIV Agents
0
Rilpivirine
FI96A8X663
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
38Investigateurs
A Harxhi
(A)
M Losso
(M)
M Kundro
(M)
B Schmied
(B)
I Karpov
(I)
A Vassilenko
(A)
D Paduto
(D)
V M Mitsura
(VM)
N Clumeck
(N)
S De Wit
(S)
M Delforge
(M)
V Hadziosmanovic
(V)
J Begovac
(J)
L Machala
(L)
D Jilich
(D)
J Gerstoft
(J)
C Pedersen
(C)
D Sedlacek
(D)
G Kronborg
(G)
T Benfield
(T)
I S Johansen
(IS)
L Ostergaard
(L)
L Wiese
(L)
N F Moller
(NF)
L N Nielsen
(LN)
K Zilmer
(K)
Jelena Smidt
(J)
I Aho
(I)
J P Viard
(JP)
P M Girard
(PM)
C Pradier
(C)
E Fontas
(E)
C Duvivier
(C)
J Rockstroh
(J)
O Degen
(O)
C Hoffmann
(C)
H J Stellbrink
(HJ)
C Stefan
(C)
J Bogner
(J)
G Fätkenheuer
(G)
N Chkhartishvili
(N)
H Sambatakou
(H)
G Adamis
(G)
N Paissios
(N)
V Uzdaviniene
(V)
T Staub
(T)
S Dragas
(S)
P Reiss
(P)
J Trajanovska
(J)
D H Reikvam
(DH)
A Maeland
(A)
J Bruun
(J)
B Knysz
(B)
B Szetela
(B)
M Inglot
(M)
E Bakowska
(E)
R Flisiak
(R)
A Grzeszczuk
(A)
M Parczewski
(M)
K Maciejewska
(K)
B Aksak-Was
(B)
M Beniowski
(M)
E Mularska
(E)
E Jablonowska
(E)
J Kamerys
(J)
K Wojcik
(K)
I Mozer-Lisewska
(I)
B Rozplochowski
(B)
A Zagalo
(A)
R Radoi
(R)
C Oprea
(C)
A Yakovlev
(A)
T Trofimora
(T)
I Khromova
(I)
E Kuzovatova
(E)
E Borodulina
(E)
E Vdoushkina
(E)
J Ranin
(J)
J Tomazic
(J)
J M Miro
(JM)
M Laguno
(M)
E Martinez
(E)
F Garcia
(F)
J L Blanco
(JL)
M Martinez-Rebollar
(M)
J Mallolas
(J)
P Callau
(P)
J Rojas
(J)
S Moreno
(S)
S Del Campo
(S)
A Jou
(A)
R Paredes
(R)
J Puig
(J)
J M Llibre
(JM)
J R Santos
(JR)
P Domingo
(P)
M Gutierrez
(M)
G M Mateo
(GM)
A Sambeat
(A)
J M Laporte
(JM)
V Svedhem
(V)
A Thalme
(A)
A Sonnerborg
(A)
L Flamholc
(L)
K Kusejko
(K)
R Weber
(R)
A Calmy
(A)
H Furrer
(H)
M Battegay
(M)
P Schmid
(P)
A Kuznetsova
(A)
J Mikhalik
(J)
M Sluzhynska
(M)
A Milinkovic
(A)
A M Johnson
(AM)
E Simons
(E)
S Edwards
(S)
A M Phillips
(AM)
A Johnson
(A)
A Mocroft
(A)
C Orkin
(C)
A Winston
(A)
A Clarke
(A)
C Leen
(C)
Informations de copyright
© 2022. The Author(s).
Références
HIV Med. 2018 May 30;:
pubmed: 29846042
HIV Clin Trials. 2013 Sep-Oct;14(5):216-23
pubmed: 24144898
HIV Clin Trials. 2013 May-Jun;14(3):81-91
pubmed: 23835510
HIV Med. 2020 Feb;21(2):71-83
pubmed: 31647187
HIV Clin Trials. 2015 Jan-Feb;16(1):30-8
pubmed: 25777187
Antivir Ther. 2018;23(2):139-148
pubmed: 28799920
AIDS. 2014 Jan 28;28(3):335-44
pubmed: 24670520
AIDS. 2010 Jan 2;24(1):55-65
pubmed: 19926964
Epidemiology. 2011 Jul;22(4):516-23
pubmed: 21522013
AIDS. 2003 May 23;17(8):1179-93
pubmed: 12819520
Viruses. 2015 Dec 07;7(12):6360-70
pubmed: 26690199
Antivir Ther. 2013;18(8):967-77
pubmed: 23714781
Drug Saf. 2016 Oct;39(10):945-57
pubmed: 27534750
BMC Infect Dis. 2017 Jul 6;17(1):476
pubmed: 28683720
J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):318-26
pubmed: 24525469